Neurogene Total Assets vs Net Debt Analysis
| NGNE Stock | 22.36 0.28 1.24% |
Neurogene financial indicator trend analysis is infinitely more than just investigating Neurogene recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurogene is a good investment. Please check the relationship between Neurogene Total Assets and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.
Total Assets vs Net Debt
Total Assets vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurogene Total Assets account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Neurogene's Total Assets and Net Debt is -0.39. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Net Debt in the same time period over historical financial statements of Neurogene, assuming nothing else is changed. The correlation between historical values of Neurogene's Total Assets and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Neurogene are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Assets i.e., Neurogene's Total Assets and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.39 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Total Assets
Total assets refers to the total amount of Neurogene assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neurogene books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Neurogene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurogene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.As of December 23, 2024, Selling General Administrative is expected to decline to about 10.4 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 76.8 M
| 2022 | 2023 | 2024 (projected) | Net Interest Income | 1.3M | 2.9M | 1.6M | Cost Of Revenue | 3.2M | 3.3M | 2.4M |
Neurogene fundamental ratios Correlations
Click cells to compare fundamentals
Neurogene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurogene fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 147.0M | 210.5M | 101.5M | 109.3M | 222.6M | 155.8M | |
| Short Long Term Debt Total | 1.2M | 12.1M | 5.2M | 4.7M | 16.3M | 17.1M | |
| Other Current Liab | 2.5M | 5.9M | 4.6M | 5.3M | 17.5M | 18.4M | |
| Total Current Liabilities | 4.7M | 7.9M | 10.9M | 6.7M | 23.0M | 24.1M | |
| Total Stockholder Equity | 141.7M | 191.2M | (91.9M) | (145.7M) | 186.0M | 195.3M | |
| Property Plant And Equipment Net | 2.8M | 13.7M | 27.5M | 24.5M | 21.0M | 12.6M | |
| Net Debt | (141.9M) | (180.4M) | (65.3M) | (77.3M) | (132.0M) | (138.6M) | |
| Retained Earnings | (299.5M) | (332.8M) | (95.6M) | (150.8M) | (187.2M) | (196.5M) | |
| Cash | 143.1M | 192.6M | 70.5M | 82.0M | 148.2M | 109.7M | |
| Non Current Assets Total | 3.4M | 16.0M | 27.5M | 24.5M | 22.2M | 20.2M | |
| Non Currrent Assets Other | 597.0K | 2.3M | (878K) | 87K | 764K | 480.6K | |
| Cash And Short Term Investments | 143.1M | 192.6M | 70.5M | 82.0M | 197.2M | 133.8M | |
| Common Stock Shares Outstanding | 27.0M | 51.8M | 55.0M | 12.8M | 14.7M | 14.0M | |
| Liabilities And Stockholders Equity | 147.0M | 210.5M | 101.5M | 109.3M | 222.6M | 155.8M | |
| Non Current Liabilities Total | 593K | 11.4M | 182.5M | 248.4M | 13.6M | 12.9M | |
| Other Current Assets | 503K | 2.0M | 3.4M | 1.7M | 2.6M | 1.6M | |
| Other Stockholder Equity | 441.2M | 524.0M | 3.8M | 5.1M | 373.2M | 224.1M | |
| Total Liab | 5.3M | 19.3M | 193.4M | 255.0M | 36.5M | 34.7M | |
| Total Current Assets | 143.6M | 194.5M | 74.0M | 84.7M | 200.3M | 135.7M | |
| Accounts Payable | 1.6M | 1.3M | 5.6M | 625K | 2.6M | 2.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.106 | Return On Assets (0.32) | Return On Equity (0.41) |
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.